Kevin Wolfe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kevin Wolfe has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Amanda E. Brooks
Department of Research in Scholarly Activity, College of Osteopathic Medicine, Rocky Vista University, Ivins, UT 84738, USA
1 shared publication - Jenifer A. Fisher
Department of Medical Humanities, Rocky Vista University, 8401 S. Chambers Road, Parker, CO 80134, USA
1 shared publication - Zachary Vinton
Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA, unmc.edu
1 shared publication
Latest Publications
- Open Access
- 5 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (7) , 2717
The Effect of Celecoxib on the Progression of Calcific Aortic Valve Disease—Protective or Pathogenic?
Calcific aortic valve disease (CAVD) is a debilitating condition for which there are limited therapeutic options aside from valve replacement. As such, it is crucial to explore alternative management strategies for CAVD. Non-steroidal anti-inflammatory drugs (NSAIDs), particularly celecoxib, have been the subject of debate in the literature regarding their potential impact on CAVD. We conducted an in-depth analysis of five studies exploring the effect of celecoxib on CAVD and found discrepancies in both methods and results. Our findings suggest that celecoxib may impact the development of this disease via multiple mechanisms, each of which may have different effects on its pathogenesis. We also discovered limited clinical research examining the connection between celecoxib use and CAVD in medical patients. As such, further studies are needed to clarify the role of celecoxib and other NSAIDs in CAVD progression in order to inform future treatment options and clarify their impact on the disease.
- 5 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (7) , 2717
Open AccessThe Effect of Celecoxib on the Progression of Calcific Aortic Valve Disease—Protective or Pathogenic?
Calcific aortic valve disease (CAVD) is a debilitating condition for which there are limited therapeutic options aside from valve replacement. As such, it is crucial to explore alternative management strategies for CAVD. Non-steroidal anti-inflammatory drugs (NSAIDs), particularly celecoxib, have been the subject of debate in the literature regarding their potential impact on CAVD. We conducted an in-depth analysis of five studies exploring the effect of celecoxib on CAVD and found discrepancies in both methods and results. Our findings suggest that celecoxib may impact the development of this disease via multiple mechanisms, each of which may have different effects on its pathogenesis. We also discovered limited clinical research examining the connection between celecoxib use and CAVD in medical patients. As such, further studies are needed to clarify the role of celecoxib and other NSAIDs in CAVD progression in order to inform future treatment options and clarify their impact on the disease.